UCB SA has confirmed that revenue for 2011 should be in the range of €3 to €3.1 billion, or below the company’s 2010 revenue of €3.2 billion, as it makes the transition from a legacy portfolio to one anchored in new patent-protected products.
Ipsen SA, reported a 7.5% rise in group drug sales to €277.3 million in the first 2011 quarter. At constant exchanges rates the gain was 6.3%.
The US Food and Drug Administration has approved the proton pump inhibitor, Nexium (esomeprazole sodium), for use in children one month and older for the short-term treatment of gastroesophageal reflux disease, AstraZeneca announced.
The US Food and Drug Administration has announced the approval of a new drug for Type 2 diabetes, Tradjenta (linagliptin). The drug was developed by Boehringer Ingelheim which has a commercialisation deal for the drug with Eli Lilly.
Wilex AG is to receive $19 million upfront as part of a licensing deal with Prometheus Laboratories Inc giving the San Diego-based company exclusive US commercialisation rights to its cancer antibody, Rencarex (girentuximab).
MorphoSys AG had a €18.8 million net profit in the 2011 first quarter on revenues that more than doubled as a consequence of a double-digit million Euro milestone payment from Novartis which installed Morphosys’s antibody library at its headquarters.
Four multinational pharmaceutical companies are among 10 new members of a consortium that has been formed to reach consensus on standards and tools for developing new drugs to treat tuberculosis that might then be adopted by drug regulators.
Novo Nordisk A/S continued to enjoy strong revenue from its diabetes franchise in the 2011 first quarter with sales up by 15% in Danish kroner and 11% in local currencies. The operating profit rose by 24%, giving an operating margin of 34.5%.
The US Food and Drug Administration has approved Zytiga (abiraterone acetate), in combination with prednisone, for the treatment of patients with late-stage castration-resistant prostate cancer. The developer is the J&J company, Centocor Ortho Biotech.
Sanofi-Aventis SA reported a 1.5% decline in net sales to €7,779 million in the first 2011quarter while its net income fell by 28.9% to €1,218 million.The results were influenced by an absence of orders for the H1N1 flu vaccine and generic competition.